LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

Recruiting now

Conditions studied: Lung Cancer

In brief

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

Key facts

Study ID

NCT04733430

Run by

Karl Landsteiner Institute for Lung Research and Pneumological Oncology

People needed

500

Starts

2020-04-17

Expected to finish

2030-04-01

Last updated by the study team

2024-03-18

Who can join

Age: 18 and older, up to 125. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent
• Histologically confirmed lung cancer
• Age ≥ 18 years
• Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments

Where it is running

• Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie — Vienna, Austria (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.